B
Braidwell Portfolio holdings
AUM
$2.7B
Turnover
43.12%
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
+3.75%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3B
AUM Growth
-$129M
(-4.1%)
Cap. Flow
-$282M
Cap. Flow
% of AUM
-9.39%
Top 10 Holdings %
Top 10 Hldgs %
30.38%
Holding
102
New
28
Increased
19
Reduced
31
Closed
14
Avg Time Held
0.9
years
Top 10 Avg Time Held
0.9
years
Top 20 Avg Time Held
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iRhythm Holdings
IRTC
|
+$56.7M |
| 2 |
Guardant Health
GH
|
+$50.2M |
| 3 |
Generate Biomedicines
GENB
|
+$43.9M |
| 4 |
Monte Rosa Therapeutics
GLUE
|
+$43.2M |
| 5 |
argenx
ARGX
|
+$42.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewise Therapeutics
EWTX
|
+$82.6M |
| 2 |
Align Technology
ALGN
|
+$59.5M |
| 3 |
CG Oncology
CGON
|
+$50.2M |
| 4 |
RAPT Therapeutics
RAPT
|
+$31.5M |
| 5 |
Legend Biotech
LEGN
|
+$28.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.27% |
| 2 | Miscellaneous | 12.42% |
| 3 | Financials | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Repligen
RGEN
$11.4B
| $5.6M | 0.19% |
47,500
-34,290
| -42% | -$4.79M |
2023 Q2
11 quarters
|
|
77
Harrow
HROW
$1.03B
| $5.52M | 0.18% |
156,419
-138,872
| -47% | -$6.1M |
2023 Q1
12 quarters
|
|
78
Revvity
RVTY
$17.1B
| $4.24M | 0.14% |
+48,400
| New | +$4.79M |
2026 Q1
0 quarters
|
|
79
Celcuity
CELC
$2.96B
| $3.33M | 0.11% |
+29,198
| New | +$3.18M |
2026 Q1
0 quarters
|
|
80
Praxis Precision Medicines
PRAX
$6.74B
| $3.21M | 0.11% |
+9,976
| New | +$3.09M |
2026 Q1
0 quarters
|
|
81
Pulmonx
LUNG
$76M
| $971K | 0.03% |
752,541
| – | – |
2022 Q4
13 quarters
|
|
|
YARW
82
Yarrow Bioscience
YARW
$158M
| $547K | 0.02% |
+18,322
| New | +$534K |
2026 Q1
0 quarters
|
|
83
Adaptive Biotechnologies
ADPT
$4.09B
| – | – |
-311,991
| Closed | -$5.07M | – |
|
|
84
Align Technology
ALGN
$10.1B
| – | – |
-381,004
| Closed | -$59.5M | – |
|
85
Biogen
BIIB
$34.3B
| – | – |
-115,700
| Closed | -$20.4M | – |
|
86
Castle Biosciences
CSTL
$1.01B
| – | – |
-177,183
| Closed | -$6.89M | – |
|
87
Icon
ICLR
$12.9B
| – | – |
-73,370
| Closed | -$13.4M | – |
|
88
Karyopharm Therapeutics
KPTI
$7.76M
| – | – |
-303,370
| Closed | -$2.23M | – |
|
|
89
Legend Biotech
LEGN
$3.77B
| – | – |
-1,298,142
| Closed | -$28.2M | – |
|
|
90
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-929,694
| Closed | -$31.5M | – |
|
91
Relmada Therapeutics
RLMD
$347M
| – | – |
-1,582,257
| Closed | -$7.64M | – |
|
92
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-575,321
| Closed | -$23.2M | – |
|
93
DELISTED
Ventyx Biosciences
VTYX
| – | – |
-1,920,255
| Closed | -$17.3M | – |
|
94
Xencor
XNCR
$1.78B
| – | – |
-459,166
| Closed | -$7.03M | – |
|
95
Oruka Therapeutics
ORKA
$5.09B
| – | – |
-84,795
| Closed | -$2.57M | – |
|
96
BillionToOne Inc
BLLN
$4.61B
| – | – |
-50,000
| Closed | -$4.09M | – |
|
Similar funds
M
AG
NIM
GC
CCM
ACP
GBCP
SCM
Braidwell's Q1 2026 Portfolio in Review
As of Q1 2026, Braidwell held 102 positions worth $3B, down 4.1% from $3.13B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Braidwell withdrew a net $282M in Q1 2026, closing 14 positions and reducing 31 holdings. Its most notable exit was Align Technology, an estimated $59.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Braidwell opened a new position in Guardant Health worth $46.2M.
- Braidwell's largest Q1 2026 buy was Guardant Health: 499,712 shares worth $46.2M.
- Braidwell added most to iRhythm Holdings in Q1 2026, an estimated $56.7M increase.
- Braidwell's biggest Q1 2026 reduction was Edgewise Therapeutics, cutting an estimated $82.6M.
- Braidwell fully exited Align Technology in Q1 2026, selling an estimated $59.5M.
- Braidwell's ten largest holdings make up 30% of its $3B portfolio in Q1 2026.
- Braidwell opened 28 new positions and closed 14 in Q1 2026.
- Braidwell's portfolio value fell 4.1% quarter-over-quarter to $3B.
Based on Braidwell's 13F filing for Q1 2026, filed 15 May 2026.